Anaesthetic formulation comprising an NMDA-antagoinst and an alpha-2 adrenergic agonist
US6562855B1 · kind B1 · utility
16Cited by
3References
6Claims
0Family size
Inventors
Key dates
| Filing date | Dec 11, 2001 |
| Grant date | May 13, 2003 |
| Priority date | — |
| Expiry date | Dec 11, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical composition is described. The composition comprises a formulation. The formulation comprises an NMDA antagonist and an alpha-2 adrenergic agonist. In a preferred aspect, there is provided an improved anaesthetic comprising an NMDA antagonist and an alpha-2 adrenergic agonist.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.